Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20091148 | 0.77 | — | — | |
| SCHEMBL25681994 | 0.77 | HTR1A (0.31) | HTR1AHTR1DHTR1B | |
| SCHEMBL28345278 | 0.74 | — | — | |
| SCHEMBL28826284 | 0.74 | CXCR2 (0.33) | CXCR2CXCR1 | |
| SCHEMBL6567061 | 0.72 | HTR1A (0.33) | HTR1AHTR1DHTR1B | |
| SCHEMBL28345281 | 0.72 | — | — | |
| Trimethylammonium SCHEMBL27553027 | 0.70 | CA1 (0.30) | CA1CA2CA7CA13 | |
| SCHEMBL1332156 | 0.67 | — | — | |
| SCHEMBL16998538 | 0.67 | — | — | |
| SCHEMBL31247237 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190659-A1 | ANGIOGENESIS INHIBITORS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2421882-A2 | ANGIOGENESIS INHIBITORS | President and Fellows of Harvard College (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123545-A2 | ANGIOGENESIS INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190659-A1 | ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | CA1 3259/4885CA2 1366/4885CA7 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.